EP Patent

EP3322708A1 — Method for purifying idelalisib

Assigned to Synthon BV · Expires 2018-05-23 · 8y expired

What this patent protects

The present invention relates to a new purification process of idelalisib (1). The process includes the steps of creating an acid addition salt of idelalisib and precipitation or crystallisation of such a salt..

USPTO Abstract

The present invention relates to a new purification process of idelalisib (1). The process includes the steps of creating an acid addition salt of idelalisib and precipitation or crystallisation of such a salt..

Drugs covered by this patent

Patent Metadata

Patent number: EP3322708A1
Jurisdiction: EP
Classification: —
Expires: 2018-05-23
Drug substance claim: No
Drug product claim: No
Assignee: Synthon BV
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.